Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.

Katagi H, Louis N, Unruh D, Sasaki T, He X, Zhang A, Ma Q, Piunti A, Shimazu Y, Lamano JB, Carcaboso AM, Tian X, Seluanov A, Gorbunova V, Laurie KL, Kondo A, Wadhwani NR, Lulla R, Goldman S, Venneti S, Becher OJ, Zou L, Shilatifard A, Hashizume R.

Clin Cancer Res. 2019 Jun 21. pii: clincanres.3890.2018. doi: 10.1158/1078-0432.CCR-18-3890. [Epub ahead of print]

PMID:
31227500
2.

ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.

Tsvankin V, Hashizume R, Katagi H, Herndon JE, Lascola C, Venkatraman TN, Picard D, Burrus B, Becher OJ, Thompson EM.

Neurosurgery. 2019 Jun 21. pii: nyz212. doi: 10.1093/neuros/nyz212. [Epub ahead of print]

PMID:
31225627
3.

Identification of novel RAS signaling therapeutic vulnerabilities in Diffuse Intrinsic Pontine Gliomas.

Koncar RF, Dey BR, Stanton AJ, Agrawal N, Wassell ML, McCarl LH, Locke AL, Sanders L, Morozova Vaske O, Myers MI, Hamilton RL, Carcaboso AM, Kohanbash G, Hu B, Amankulor NM, Felker J, Kambhampati M, Nazarian J, Becher OJ, James CD, Hashizume R, Broniscer A, Pollack IF, Agnihotri S.

Cancer Res. 2019 Jun 14. pii: canres.3521.2018. doi: 10.1158/0008-5472.CAN-18-3521. [Epub ahead of print]

PMID:
31201162
4.

Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease.

Qi J, Esfahani DR, Huang T, Ozark P, Bartom E, Hashizume R, Bonner ER, An S, Horbinski CM, James CD, Saratsis AM.

Acta Neuropathol Commun. 2019 May 15;7(1):75. doi: 10.1186/s40478-019-0727-1.

5.

Global Reduction of H3K4me3 Improves Chemotherapeutic Efficacy for Pediatric Ependymomas.

Lewis R, Li YD, Hoffman L, Hashizume R, Gravohac G, Rice G, Wadhwani NR, Jie C, Pundy T, Mania-Farnell B, Mayanil CS, Soares MB, Lei T, James CD, Foreman NK, Tomita T, Xi G.

Neoplasia. 2019 Jun;21(6):505-515. doi: 10.1016/j.neo.2019.03.012. Epub 2019 Apr 18.

6.

Potent Antineoplastic Effects of Combined PI3Kα-MNK Inhibition in Medulloblastoma.

Eckerdt F, Bell JB, Beauchamp EM, Clymer J, Blyth GT, Kosciuczuk EM, Ma Q, Chen DZ, Horbinski C, Goldman S, Munshi HG, Hashizume R, Platanias LC.

Mol Cancer Res. 2019 Jun;17(6):1305-1315. doi: 10.1158/1541-7786.MCR-18-1193. Epub 2019 Mar 6.

PMID:
30842251
7.

ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.

Hoeman CM, Cordero FJ, Hu G, Misuraca K, Romero MM, Cardona HJ, Nazarian J, Hashizume R, McLendon R, Yu P, Procissi D, Gadd S, Becher OJ.

Nat Commun. 2019 Mar 4;10(1):1023. doi: 10.1038/s41467-019-08823-9.

8.

Molecular and translational advances in meningiomas.

Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM, Hashizume R, James CD, Mawrin C, Noushmehr H, Perry A, Sahm F, Sloan A, Von Deimling A, Wen PY, Aldape K, Zadeh G; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jan 14;21(Supplement_1):i4-i17. doi: 10.1093/neuonc/noy178.

PMID:
30649490
9.

Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy.

Liang K, Smith ER, Aoi Y, Stoltz KL, Katagi H, Woodfin AR, Rendleman EJ, Marshall SA, Murray DC, Wang L, Ozark PA, Mishra RK, Hashizume R, Schiltz GE, Shilatifard A.

Cell. 2018 Oct 18;175(3):766-779.e17. doi: 10.1016/j.cell.2018.09.027.

PMID:
30340042
10.
11.

Measuring Tumor Metabolism in Pediatric Diffuse Intrinsic Pontine Glioma Using Hyperpolarized Carbon-13 MR Metabolic Imaging.

Autry AW, Hashizume R, James CD, Larson PEZ, Vigneron DB, Park I.

Contrast Media Mol Imaging. 2018 Jul 30;2018:3215658. doi: 10.1155/2018/3215658. eCollection 2018.

12.

CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response.

Stallard S, Savelieff MG, Wierzbicki K, Mullan B, Miklja Z, Bruzek A, Garcia T, Siada R, Anderson B, Singer BH, Hashizume R, Carcaboso AM, McMurray KQ, Heth J, Muraszko K, Robertson PL, Mody R, Venneti S, Garton H, Koschmann C.

Acta Neuropathol Commun. 2018 Aug 15;6(1):80. doi: 10.1186/s40478-018-0580-7. No abstract available.

13.

MELK Inhibition in Diffuse Intrinsic Pontine Glioma.

Meel MH, de Gooijer MC, Guillén Navarro M, Waranecki P, Breur M, Buil LCM, Wedekind LE, Twisk JWR, Koster J, Hashizume R, Raabe EH, Montero Carcaboso A, Bugiani M, van Tellingen O, van Vuurden DG, Kaspers GJL, Hulleman E.

Clin Cancer Res. 2018 Nov 15;24(22):5645-5657. doi: 10.1158/1078-0432.CCR-18-0924. Epub 2018 Jul 30.

PMID:
30061363
14.

Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.

Wang L, Zhao Z, Ozark PA, Fantini D, Marshall SA, Rendleman EJ, Cozzolino KA, Louis N, He X, Morgan MA, Takahashi YH, Collings CK, Smith ER, Ntziachristos P, Savas JN, Zou L, Hashizume R, Meeks JJ, Shilatifard A.

Nat Med. 2018 Jun;24(6):758-769. doi: 10.1038/s41591-018-0034-6. Epub 2018 May 21.

15.

Renal papillary tip extract stimulates BNP production and excretion from cardiomyocytes.

Goto I, Okamoto R, Hashizume R, Suzuki N, Ito R, Yamanaka K, Saito H, Kiyonari H, Tawara I, Kageyama Y, Ogihara Y, Ali Y, Yamada N, Katayama N, Ito M.

PLoS One. 2018 May 7;13(5):e0197078. doi: 10.1371/journal.pone.0197078. eCollection 2018.

16.

Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma.

Sredni ST, Bailey AW, Suri A, Hashizume R, He X, Louis N, Gokirmak T, Piper DR, Watterson DM, Tomita T.

Oncotarget. 2017 Nov 24;8(67):111190-111212. doi: 10.18632/oncotarget.22704. eCollection 2017 Dec 19.

17.

New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model.

Louis N, Liu S, He X, Drummond DC, Noble CO, Goldman S, Mueller S, Bankiewicz K, Gupta N, Hashizume R.

J Neurooncol. 2018 Feb;136(3):475-484. doi: 10.1007/s11060-017-2681-8. Epub 2017 Nov 23.

18.

A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism.

Wang L, Collings CK, Zhao Z, Cozzolino KA, Ma Q, Liang K, Marshall SA, Sze CC, Hashizume R, Savas JN, Shilatifard A.

Genes Dev. 2017 Oct 15;31(20):2056-2066. doi: 10.1101/gad.306092.117. Epub 2017 Nov 14.

19.

Sentinel Node Navigation Surgery for Early Gastric Cancer: Analysis of Factors Which Affect Direction of Lymphatic Drainage.

Shida A, Mitsumori N, Fujioka S, Takano Y, Fujisaki M, Hashizume R, Takahashi N, Ishibashi Y, Yanaga K.

World J Surg. 2018 Mar;42(3):766-772. doi: 10.1007/s00268-017-4226-x.

PMID:
28920152
20.

Comparison of Postoperative Outcomes Between Laparoscopic and Open Surgery for Colorectal Cancer.

Neki K, Eto K, Kosuge M, Ohkuma M, Noaki R, Hashizume R, Sasaki S, Shirai Y, Yanaga K.

Anticancer Res. 2017 Sep;37(9):5173-5177.

PMID:
28870951
21.

Which Is the Safer Anastomotic Method for Colon Surgery? - Ten-year Results.

Kosuge M, Eto K, Hashizume R, Takeda M, Tomori K, Neki K, Mitsumori N, Yanaga K.

In Vivo. 2017 Jul-Aug;31(4):683-687.

22.
23.

Cytological features of adenocarcinoma admixed with small cell neuroendocrine carcinoma of the uterine cervix.

Shimojo N, Hirokawa YS, Kanayama K, Yoneda M, Hashizume R, Hayashi A, Uchida K, Imai H, Kozuka Y, Shiraishi T.

Cytojournal. 2017 May 26;14:12. doi: 10.4103/1742-6413.207139. eCollection 2017.

24.

Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma.

Hashizume R.

Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):331-342. doi: 10.2176/nmc.ra.2017-0018. Epub 2017 Jun 7. Review.

25.

Use of a pedicled omental flap to reduce inflammation and vascularize an abdominal wall patch.

Uchibori T, Takanari K, Hashizume R, Amoroso NJ, Kamei Y, Wagner WR.

J Surg Res. 2017 May 15;212:77-85. doi: 10.1016/j.jss.2016.11.052. Epub 2016 Dec 6.

PMID:
28550925
26.

Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG.

Cordero FJ, Huang Z, Grenier C, He X, Hu G, McLendon RE, Murphy SK, Hashizume R, Becher OJ.

Mol Cancer Res. 2017 Sep;15(9):1243-1254. doi: 10.1158/1541-7786.MCR-16-0389. Epub 2017 May 18.

27.

A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2.

Zhou J, Tien AC, Alberta JA, Ficarro SB, Griveau A, Sun Y, Deshpande JS, Card JD, Morgan-Smith M, Michowski W, Hashizume R, James CD, Ligon KL, Snider WD, Sicinski P, Marto JA, Rowitch DH, Stiles CD.

Cell Rep. 2017 Mar 28;18(13):3167-3177. doi: 10.1016/j.celrep.2017.03.003.

28.

Therapeutic Hypothesis Testing With Rodent Brain Tumor Models.

Wainwright DA, Horbinski CM, Hashizume R, James CD.

Neurotherapeutics. 2017 Apr;14(2):385-392. doi: 10.1007/s13311-017-0523-1. Review.

29.

Enhanced Recovery After Surgery Programs for Laparoscopic Colorectal Resection May Not Need Thoracic Epidural Analgesia.

Eto K, Kondo I, Kosuge M, Ohkuma M, Haruki K, Neki K, Sugano H, Hashizume R, Yanaga K.

Anticancer Res. 2017 Mar;37(3):1359-1364.

PMID:
28314303
30.

Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.

Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, Misharin AV, Abshiru NA, Lulla RR, Saratsis AM, Kelleher NL, James CD, Shilatifard A.

Nat Med. 2017 Apr;23(4):493-500. doi: 10.1038/nm.4296. Epub 2017 Feb 27.

31.

Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies.

Maury E, Hashizume R.

Epigenetics. 2017 May 4;12(5):353-369. doi: 10.1080/15592294.2016.1278095. Epub 2017 Jan 6. Review.

32.

Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.

Zhang J, Yao TW, Hashizume R, Hariono S, Barkovich KJ, Fan QW, Prados M, James CD, Weiss WA, Nicolaides T.

J Neurooncol. 2017 Feb;131(3):495-505. doi: 10.1007/s11060-016-2333-4. Epub 2016 Nov 15.

33.

Skeletal muscle derived stem cells microintegrated into a biodegradable elastomer for reconstruction of the abdominal wall.

Takanari K, Hashizume R, Hong Y, Amoroso NJ, Yoshizumi T, Gharaibeh B, Yoshida O, Nonaka K, Sato H, Huard J, Wagner WR.

Biomaterials. 2017 Jan;113:31-41. doi: 10.1016/j.biomaterials.2016.10.029. Epub 2016 Oct 18.

PMID:
27810640
34.

BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.

Olow A, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss W, Resnick AC, Waanders AJ, Stalpers LJ, Berger MS, Gupta N, James CD, Petritsch CK, Haas-Kogan DA.

Clin Cancer Res. 2016 Nov 1;22(21):5312-5321. Epub 2016 May 23.

35.

A polymethoxyflavone mixture, extracted from orange peels, suppresses the UVB-induced expression of MMP-1.

Yoshizaki N, Fujii T, Hashizume R, Masaki H.

Exp Dermatol. 2016 Aug;25 Suppl 3:52-6. doi: 10.1111/exd.13087.

PMID:
27539903
36.

Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.

Hashizume R, Zhang A, Mueller S, Prados MD, Lulla RR, Goldman S, Saratsis AM, Mazar AP, Stegh AH, Cheng SY, Horbinski C, Haas-Kogan DA, Sarkaria JN, Waldman T, James CD.

Neuro Oncol. 2016 Nov;18(11):1519-1528. Epub 2016 Jul 1.

37.

Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas.

Hashizume R, Gupta N.

Curr Neuropharmacol. 2017;15(1):98-103. Review.

38.

Mutations in chromatin machinery and pediatric high-grade glioma.

Lulla RR, Saratsis AM, Hashizume R.

Sci Adv. 2016 Mar 18;2(3):e1501354. doi: 10.1126/sciadv.1501354. eCollection 2016 Mar. Review.

39.

Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma.

Clark AJ, Fakurnejad S, Ma Q, Hashizume R.

J Vis Exp. 2016 Jan 15;(107):e53287. doi: 10.3791/53287.

40.

Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.

Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA.

J Neurooncol. 2016 Feb;126(3):395. doi: 10.1007/s11060-015-2024-6. No abstract available.

PMID:
26782702
41.

Erratum to: A 1-bp deletion in Fgf5 causes male-dominant long hair in the Syrian hamster.

Yoshizawa Y, Wada K, Shimoi G, Kameyama Y, Wakabayashi Y, Fukuta K, Hashizume R.

Mamm Genome. 2016 Feb;27(1-2):98. doi: 10.1007/s00335-015-9617-4. No abstract available.

PMID:
26689206
42.

Imidazoquinolines: Recent Developments in Anticancer Activity.

Patil SA, Patil SA, Patil R, Hashizume R.

Mini Rev Med Chem. 2016;16(4):309-22. Review.

PMID:
26675675
43.

Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.

Lerner RG, Grossauer S, Kadkhodaei B, Meyers I, Sidorov M, Koeck K, Hashizume R, Ozawa T, Phillips JJ, Berger MS, Nicolaides T, James CD, Petritsch CK.

Cancer Res. 2015 Dec 15;75(24):5355-66. doi: 10.1158/0008-5472.CAN-14-3689. Epub 2015 Nov 16.

44.

A 1-bp deletion in Fgf5 causes male-dominant long hair in the Syrian hamster.

Yoshizawa Y, Wada K, Shimoi G, Kameyama Y, Wakabayashi Y, Fukuta K, Hashizume R.

Mamm Genome. 2015 Dec;26(11-12):630-7. doi: 10.1007/s00335-015-9608-5. Epub 2015 Oct 19. Erratum in: Mamm Genome. 2016 Feb;27(1-2):98. Shiomi, Gaku [Corrected to Shimoi, Gaku].

PMID:
26481120
45.

Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.

Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA.

J Neurooncol. 2016 Feb;126(3):385-93. doi: 10.1007/s11060-015-1939-2. Epub 2015 Sep 18. Erratum in: J Neurooncol. 2016 Feb;126(3):395.

46.

EAG2 potassium channel with evolutionarily conserved function as a brain tumor target.

Huang X, He Y, Dubuc AM, Hashizume R, Zhang W, Reimand J, Yang H, Wang TA, Stehbens SJ, Younger S, Barshow S, Zhu S, Cooper MK, Peacock J, Ramaswamy V, Garzia L, Wu X, Remke M, Forester CM, Kim CC, Weiss WA, James CD, Shuman MA, Bader GD, Mueller S, Taylor MD, Jan YN, Jan LY.

Nat Neurosci. 2015 Sep;18(9):1236-46. doi: 10.1038/nn.4088. Epub 2015 Aug 10.

47.

Tenascin-C may accelerate cardiac fibrosis by activating macrophages via the integrin αVβ3/nuclear factor-κB/interleukin-6 axis.

Shimojo N, Hashizume R, Kanayama K, Hara M, Suzuki Y, Nishioka T, Hiroe M, Yoshida T, Imanaka-Yoshida K.

Hypertension. 2015 Oct;66(4):757-66. doi: 10.1161/HYPERTENSIONAHA.115.06004. Epub 2015 Aug 3.

PMID:
26238448
48.

Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic.

Morales La Madrid A, Hashizume R, Kieran MW.

Front Oncol. 2015 Jul 1;5:148. doi: 10.3389/fonc.2015.00148. eCollection 2015. Review.

49.

Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells.

Clark AJ, Safaee M, Oh T, Ivan ME, Parimi V, Hashizume R, Ozawa T, James CD, Bloch O, Parsa AT.

J Transl Med. 2014 Dec 3;12:345. doi: 10.1186/s12967-014-0345-4.

50.

Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma.

Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, Huang X, Tom MW, Ngo V, Solomon D, Mueller S, Paris PL, Zhang Z, Petritsch C, Gupta N, Waldman TA, James CD.

Nat Med. 2014 Dec;20(12):1394-6. doi: 10.1038/nm.3716. Epub 2014 Nov 17.

Supplemental Content

Loading ...
Support Center